Abstract
Azoles (fluconazole, itraconazole and ketoconazole) are among the few classes of antifungals available for the treatment of systemic yeast infections. Nowadays, due to the global AIDS pandemic and the use of immunosuppressive drugs in anticancer chemotherapy, the incidence of fungal infection as increased [1]. For these reasons, the resistance of yeasts to treatment is very common and the effectiveness of antifungal drugs is reduced by the activity of multidrug transporters from the ATP-binding cassette superfamily, such as Cdr1p and Cdr2p of the major human fungal pathogen Candida albicans. These proteins reduce intracellular drug concentration by actively extruding them out of cells. One of the strategies employed to overcome this type of resistance is the combination treatment with efflux pump inhibitors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
